Naina Mohamed Pakkir Maideen

(Dubai Health Authority)

Author Details

1. Naina mohamed pakkir maideen

Author Statistics

Views : 574

Downloads : 149


Article Statistics

0
This article cited by 0

Search By Keyword

Drug interactions
cyp2c8
cyp2c9
cyp3a4
nateglinide
oatp1b1 transporter
repaglinide

Article File

PDF

Drug interactions of meglitinide antidiabetics involving cyp enzymes and oatp1b1 transporter

Author : Naina mohamed pakkir maideen

Keyword : Drug interactions, cyp2c8, cyp2c9, cyp3a4, nateglinide, oatp1b1 transporter, repaglinide

Subject : Diabetes

Article Type : Review article

DOI : 10.1177/2042018818767220

Article QR Code

Drug interactions of meglitinide antidiabetics involving cyp enzymes and oatp1b1 transporter QR Code

Article File : Full Text PDF

Abstract : Meglitinides such as repaglinide and nateglinide are useful to treat type 2 diabetes patients who follow a flexible lifestyle. They are short-acting insulin secretagogues and are associated with less risk of hypoglycemia, weight gain and chronic hyperinsulinemia compared with sulfonylureas. Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions. This article focuses on the drug interactions of meglitinides involving CYP enzymes and OATP1B1 transporter. To prevent the risk of hypoglycemic episodes, prescribers and pharmacists must be aware of the adverse drug interactions of meglitinides.

Article by : Naina Mohamed Pakkir Maideen

Article add date : 2021-12-21


How to cite : Naina mohamed pakkir maideen. (2021-December-21). Drug interactions of meglitinide antidiabetics involving cyp enzymes and oatp1b1 transporter. retrieved from https://www.openacessjournal.com/abstract/930